May 02, 2022 / 07:30PM GMT
Unidentified Participant
Hi, everyone. We're ready to start our next session. So the next presenting company is Fusion Pharmaceuticals. We're joined today by John Valliant, the CEO. John, you have the floor. Thank you.
John Valliant - Fusion Pharmaceuticals Inc. - CEO
Thank you. So it's a tremendous pleasure to be able to speak to people in three dimensions and not on Zoom. And I'm very excited to tell you the story about Fusion today.
So the field of radiopharmaceuticals, a field I've been in for about 25 years, has undergone a tremendous resurgence. And it's really the idea that external beam radiation therapy is a mainstay of cancer treatments. But now the idea of bringing that cancer therapy and that radiation on a cell-by-cell basis to a wider range of disease.
So the idea is that you're going to systemically deliver radiation directly to tumor cells. It's a simple proven mechanism of action, really looking at causing DNA damage.
The type of radiation that we use, which is shown up in this corner here, is alpha-emitting radiation. Alpha
Fusion Pharmaceuticals Inc at Bloom Burton & Co. Healthcare Investor Conference Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers